4.8 Article

High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance

期刊

NATURE COMMUNICATIONS
卷 13, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-022-31818-y

关键词

-

资金

  1. Deutsche Forschungsgemeinschaft [DFG, German Research Foundation] [10088, INST 247/870-1 FUGG]
  2. Bioinformatics Core Facility
  3. Naturwissenschaftlich-Medizinische Forschungszentrum (NMFZ)
  4. Deutsche Forschungsgemeinschaft [SFB902 B13]
  5. National Institutes of Health [U01 CA232563]
  6. St. Baldrick's-Stand Up to Cancer [SU2C-AACR-DT-27-17]
  7. V Foundation for Cancer Research [T2018-014]
  8. Ellen Weisberg Fund: Advancing Breakthroughs in Pediatric Cancer

向作者/读者索取更多资源

After CART-19 immunotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), relapse often occurs due to loss of the CD19 epitope. The study investigated the regulatory code that controls CD19 splicing and identified mutations and splice isoforms that could contribute to CART-19 resistance in B-ALL patients. Additionally, regulatory elements and RNA-binding proteins that control CD19 splicing were identified, highlighting their importance in CD19 mis-splicing.
Following CART-19 immunotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), many patients relapse due to loss of the cognate CD19 epitope. Since epitope loss can be caused by aberrant CD19 exon 2 processing, we herein investigate the regulatory code that controls CD19 splicing. We combine high-throughput mutagenesis with mathematical modelling to quantitatively disentangle the effects of all mutations in the region comprising CD19 exons 1-3. Thereupon, we identify similar to 200 single point mutations that alter CD19 splicing and thus could predispose B-ALL patients to developing CART-19 resistance. Furthermore, we report almost 100 previously unknown splice isoforms that emerge from cryptic splice sites and likely encode non-functional CD19 proteins. We further identify cis-regulatory elements and trans-acting RNA-binding proteins that control CD19 splicing (e.g., PTBP1 and SF3B4) and validate that loss of these factors leads to pervasive CD19 mis-splicing. Our dataset represents a comprehensive resource for identifying predictive biomarkers for CART-19 therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据